Ignite Creation Date:
2025-12-24 @ 11:04 PM
Ignite Modification Date:
2026-02-19 @ 4:50 PM
Study NCT ID:
NCT00741169
Status:
COMPLETED
Last Update Posted:
2013-04-18
First Post:
2008-08-22
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
TMC435350-TiDP16-C105: Phase I, 3-way Crossover, Drug-drug Interaction Between TMC435350 and Rifampin After Multiple Dosing.
Sponsor:
Tibotec Pharmaceuticals, Ireland
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
CR015412
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None